Triethylenemelamine
Chemical compound
- None
- 2,4,6-Tris(aziridin-1-yl)-1,3,5-triazine
- 51-18-3 Y
- 5799
- 5594 N
- F7IY6HZG9D
- C07642 N
- ChEMBL502384 N
- DTXSID3026225
- Interactive image
- C1CN1c2nc(nc(n2)N3CC3)N4CC4
InChI
- InChI=1S/C9H12N6/c1-2-13(1)7-10-8(14-3-4-14)12-9(11-7)15-5-6-15/h1-6H2 N
- Key:IUCJMVBFZDHPDX-UHFFFAOYSA-N N
Triethylenemelamine (abbreviated TEM, also called Tretamine) is a drug used in chemotherapy.[1]
It can cause chromatid aberrations in cell models.[2]
See also
- Altretamine
References
- ^ Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, Kleinerman RA (October 2014). "Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy". Journal of Clinical Oncology. 32 (29): 3284–3290. doi:10.1200/JCO.2013.54.7844. PMC 4178525. PMID 25185089.
- ^ Luippold HE, Gooch PC, Brewen JG (February 1978). "The production of chromosome aberrations in various mammalian cells by triethylenemelamine". Genetics. 88 (2): 317–326. doi:10.1093/genetics/88.2.317. PMC 1213803. PMID 565312.
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e